When initiating Sermorelin therapy, should the dose be started at a low level and titrated upward?

Sermorelin Dosing: Start Low and Titrate Up

Yes, sermorelin therapy should be initiated at a low dose and gradually titrated upward to minimize side effects and optimize tolerability.

Dosing Strategy

Based on the available evidence for sermorelin in pediatric growth hormone deficiency, the standard approach involves:

• Starting dose: 30 mcg/kg subcutaneously once daily at bedtime 1
• Titration: While the research evidence doesn't explicitly detail a step-wise titration protocol, the general principle of starting low applies, particularly given that sermorelin is administered subcutaneously and stimulates endogenous growth hormone release

Rationale for Low-Start Approach

The principle of "start low, go slow" is well-established in medical practice for peptide therapies and medications that affect hormone systems. This approach:

• Minimizes adverse effects: The most common side effects of sermorelin include transient facial flushing and injection site pain 1. Starting at lower doses allows patients to acclimate to these effects
• Allows assessment of individual response: Growth hormone secretion varies significantly between individuals, and starting conservatively permits evaluation of each patient's specific response pattern
• Reduces risk of overstimulation: Excessive growth hormone release can cause unwanted effects

Practical Implementation

While specific titration schedules for sermorelin aren't detailed in the available evidence, the recommended approach based on clinical practice would be:

1. Initial phase: Begin at 30 mcg/kg/day (or potentially lower in sensitive patients)
2. Monitoring: Assess tolerance over the first 1-2 weeks
3. Adjustment: Increase dose gradually if needed based on clinical response and IGF-1 levels
4. Maintenance: Continue at the lowest effective dose that achieves therapeutic goals

Important Caveats

• Limited adult data: Most sermorelin evidence comes from pediatric growth hormone deficiency studies 1. Adult dosing protocols may differ
• Individual variability: Response to sermorelin varies considerably between patients, necessitating individualized dose optimization
• Monitoring required: Regular assessment of IGF-1 levels and clinical response should guide dose adjustments
• Injection site rotation: To minimize local reactions, rotate injection sites consistently

The conservative approach of starting low and titrating based on response is consistent with best practices for hormone-modulating therapies and peptide medications, even though specific titration protocols for sermorelin are not extensively documented in the literature.